Komtur Pharmaceuticals Headquarters
Am Flughafen 6
DE 79108 Freiburg im Breisgau
Telephone: +49(0)761 504 23 0
Fax: +49(0)761 504 23 15
E-Mail: info@komtur.com

Komtur Pharmaceuticals is a specialized pharmaceutical wholesaler who has been acting successfully on the international pharmaceutical market for over fifty years. We supply patients around the world with urgently needed drugs and carry out complex projects on behalf of pharmaceutical companies.

Our international team of pharmacists, qualified pharmaceutical personnel, and experienced logisticians as well as service employees is intimately familiar with the options, challenges, and regulatory requirements of the national and global pharmaceuticals trade.

Our name stands for custom-tailored solutions for supplying international drugs, sourcing and distributing trial medication, or market launching your innovative drug.

We never forget that every shipment is destined for a patient with individual needs.

From its origins as the Komtur Pharmacy in Freiburg, our company has grown to representation in six countries on three continents with over 65 employees. All subsidiaries of the Komtur Group are in constant contact with one another and work in close consultation with the company headquarters in Freiburg (Breisgau), Germany. Although our roots are in Freiburg, we are represented in core markets of our industry with our subsidiaries. This keeps us continuously updated about innovations of all kinds, new drug developments, or better transport routes.

With the exception of Shanghai, all of our subsidiaries are fully licensed pharmaceutical wholesalers.

The Komtur portfolio includes:

Our customers and partners in Germany and abroad know and appreciate Komtur Pharmaceuticals as a reliable and innovative specialized pharmaceutical wholesaler. Our aim is to keep earning your appreciation.

Go to article: Home | Gut InstinctGo to article: In this issueGo to article: TSS Company InsightGo to article: TSS ABGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: The Pharma Industry BriefingGo to article: Komtur PharmaceuticalsGo to article: Komtur Pharmaceuticals Company InsightGo to article: How will the UK’s relaxed cannabis regulations impact clinical practice?Go to article: Finnair CargoGo to article: Finnair Cargo | Company InsightGo to article: Developing a new class of cancer combo drugsGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Antidepressants in the environment: combatting pharmaceutical pollutionGo to article: AtoZ-CRO GmbHGo to article: AtoZ-CRO GmbH Company InsightGo to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: CBDepotGo to article: CBDepot Company InsightGo to article: Going digital to improve clinical trial enrolmentGo to article: BEAGo to article: Incretin combination therapy: a breakthrough for type 2 diabetes?Go to article: AlpexGo to article: Ebola in the DRC: vaccinating in a conflict zoneGo to article: Hemp IndustriesGo to article: Unither PharmaceuticalsGo to article: Data overload: turning challenges into opportunities in clinical trialsGo to article: ZenatekGo to article: Solving clinical research challenges: an IT perspectiveGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: EventsGo to article: In the next issue